Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Phase I, open label, dose-escalation, and safety study designed to assess the safety and
biologic activity of the investigational agent CBL0137 in combination with standard of care
drugs, ipilimumab and nivolumab in sequential cohorts of adult patients with locally advanced
and metastatic melanoma who are candidates for immune checkpoint blockade and have tumors
accessible for serial biopsies.